CD8A and neoplasm: Additionally, patients with low CD3+PD-1+ expression and high CD8+CD28+ expression had longer progression-free survival (PFS).<h4>Conclusion</h4>The expression of CD28 and PD-1 on T cells can serve as potential biomarkers for assessing tumor progression, chemotherapy response and prognosis in advanced BC.